Skip to content

PhRMA Dues Plummet by Nearly $100 Million as Big Pharma Exits

The Pharmaceutical Research and Manufacturers of America (PhRMA) experienced a significant drop in dues, losing almost $100 million. This decline comes as several major pharmaceutical companies, including AbbVie, Amgen, and Eli Lilly, have left the organization. PhRMA, which represents the biopharmaceutical industry, saw its revenue from dues decrease from $487 million in 2021 to $390 million in 2022. The exit of these companies was influenced by disagreements over the group’s lobbying strategies and the increasing pressure from public and political scrutiny on drug pricing. Despite the financial hit, PhRMA’s CEO, Steve Ubl, remains optimistic, stating that the organization is adapting to a changing environment. The departure of these firms highlights a shift in the industry’s approach to advocacy and representation.

Source: https://www.statnews.com/2024/12/23/phrma-membership-dues-revenue-decline-abbvie-astrazeneca-teva-quit/